ZNTL NASDAQ
Zentalis Pharmaceuticals, Inc.
1W: -17.1%
1M: -23.9%
3M: -57.6%
YTD: +44.5%
1Y: +15.8%
3Y: -89.0%
5Y: -97.4%
$1.98
-0.09 (-4.35%)
Pre-Market: $1.85 (-0.12, -6.31%)
Weekly Expected Move ±11.3%
$2
$2
$2
$2
$3
Credit Risk of going bust: higher than 80% of companies Debt: 21.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.03 (down 99%), Zentalis Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $37.7M against a stock market value of $140.9M.
Distance to default 2.58 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $4.1M (short-term plus half of long-term), stock volatility 117.5%; Altman Z'' -18.17. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.03 (down 99%), Zentalis Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $37.7M against a stock market value of $140.9M.
Distance to default 2.58 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $4.1M (short-term plus half of long-term), stock volatility 117.5%; Altman Z'' -18.17. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
3 relationships1
As Filer
counterparties named
2
As Counterparty
mentioned by others
1
Rel. Types
2023-03-09
Earliest Filing
2024-10-29
Latest Filing
partner: 1
Counterparties (Filed by ZNTL)
1 relationshipsCompanies named in ZNTL's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| ESRT 1359 BROADWAY, L.L.C. | — | partner | Landlord of the office space leased by the Company, which is being subleased to LM Cohen & Co. LLP. | 2023-03-09 | View |
Mentioned As Counterparty
2 mentionsOther companies that named ZNTL in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| IMNM Immunome Inc. | target | Zentalis acquired Immunome's licensed assets via an Asset Purchase Agreement and received common stock as consideration. | 2024-10-29 | View |
| IMNM Immunome Inc. | partner | Immunome, Inc. entered into a license agreement and stock issuance agreement with Zentalis Pharmaceuticals, Inc. for ROR | 2024-01-08 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-14 | Other Events; Exhibits | View | |
| 2026-08-06 | Earnings Release; Regulation FD | View | |
| 2026-06-18 | Shareholder Vote | View | |
| 2026-05-27 | Officer/Director Change | View | |
| 2026-05-21 | Regulation FD; Other Events | View | |
| 2026-05-12 | Earnings Release; Regulation FD | View | |
| 2026-05-05 | Regulation FD; Other Events | View | |
| 2026-04-17 | Regulation FD | View | |
| 2026-04-09 | Regulation FD; Other Events | View | |
| 2026-03-26 | Earnings Release; Exhibits | View | |
| 2026-01-09 | Regulation FD Disclosure; Other Events | View | |
| 2025-12-15 | Departure/Election of Directors; Appointment of Officers; Other Events | View | |
| 2025-11-10 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-08-26 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Regulation FD Disclosure | View | |
| 2025-06-18 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-06-02 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-05-20 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-05-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-28 | Regulation FD Disclosure; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR